Skip to main content
Catherine Coombs, MD

For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has correlated with time-to-event outcomes. Use of MRD has shown promise for guiding duration of treatment for CLL patients on time-limited therapy.

“MRD measurement is not necessarily standard of care at the moment, but it will continue to emerge as an important goal of treatment in fixed-duration CLL regimens,” said Catherine Coombs, MD, associate professor in the division of hematology, in MedPage Today. “Studies in venetoclax-based treatment have found achieving negative MRD levels to be prognostic of favorable outcomes with pronounced better PFS and OS.”

Read the article.